Skip to main content
NewslettersWatchlist

Pfizer Inc(PFE-N)
NYSE

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low24.86
Day High24.86
Open:24.86
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
the globe and mail
the globe and mail

Kinaxis ‘has not closed the door to any path’ including sale, chair says

Comments come as Ottawa software company, which faces calls from some investors to sell, continues to generate sluggish sales growth
Motley Fool
2 Beaten-Down Healthcare Stocks to Buy Hand Over Fist
Motley Fool
2 Dividend Stocks That Pay More Than 6% That Retirees Can Safely Buy and Hold for Years
Motley Fool
Is It Time to Sell Eli Lilly and Pfizer Stocks?
Newswire.ca
TAHO Pharmaceuticals Initiates U.S. Phase III Clinical Trial of TAH3311 Antithrombotic Oral Dissolving Film, Dosing First Subjects
Motley Fool
2 High-Yield Dividend Stocks I Can't Stop Buying
Barchart
Stocks Set to Open Mixed as Investors Await U.S. Economic Data and Nvidia Earnings, Fed Speak on Tap
MarketBeat
ORIC: Working with Two Pharma Giants, Analysts See +100% Upside
Stock Target Advisor
Market News & Analysis: November 15th, 2024
Barchart
Thursday's Unusual Options Activity Reveals 3 Promising Long-Term Investments
Barchart
Long Straddle Screener Results For November 14th
Barchart
Stocks Finish Mostly Higher as CPI Report Matches Expectations
Motley Fool
1 Magnificent S&P 500 Dividend Stock Down 12% to Buy After Its Recent Pullback
Motley Fool
3 Spectacular High-Yield Dividend Stocks to Buy in November
Motley Fool
2 Magnificent S&P 500 Dividend Stocks Down Year to Date to Buy and Hold Forever
Motley Fool
With Nvidia Kicking Intel Out of the Dow Jones, Will Meta Platforms or Alphabet Eventually Replace Walt Disney Stock?
Motley Fool
2 Healthcare Dividend Stocks That Are Screaming Buys in November
Motley Fool
3 Reasons Pfizer Looks Like a No-Brainer Buy Right Now
Motley Fool
2 Magnificent Stocks to Buy That Are Near 52-Week Lows
Motley Fool
1 Green Flag That's Also a Red Flag for Pfizer Stock
Barchart
Is This High-Yield Dividend Stock a Buy After Earnings?
The Globe and Mail
Pfizer struggles to find new revenue sources as vaccine sales fade, but here’s why investors shouldn’t shy away from its stock
Motley Fool
Is Pfizer Stock a Bargain for Long-Term Investors?

Profile

Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.'The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.